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Abstract
Retinal neovascularization is a critical component in the pathogenesis of common ocular disorders that cause blindness, and
treatment options are limited. We evaluated the therapeutic effect of a DNA enzyme targeting c-jun mRNA in mice with pre-
existing retinal neovascularization. A single injection of Dz13 in a lipid formulation containing N-[1-(2,3-dioleoyloxy)propyl]-
N,N,N-trimethylammonium methyl-sulfate and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine inhibited c-Jun expression
and reduced retinal microvascular density. The DNAzyme inhibited retinal microvascular density as effectively as VEGF-A
antibodies. Comparative microarray and gene expression analysis determined that Dz13 suppressed not only c-jun but a
range of growth factors and matrix-degrading enzymes. Dz13 in this formulation inhibited microvascular endothelial cell
proliferation, migration and tubule formation in vitro. Moreover, animals treated with Dz13 sensed the top of the cage in a
modified forepaw reach model, unlike mice given a DNAzyme with scrambled RNA-binding arms that did not affect c-Jun
expression. These findings demonstrate reduction of microvascular density and improvement in forepaw reach in mice
administered catalytic DNA.
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Introduction
Neovascularization is the process by which new blood vessels
are formed by the sprouting of endothelial cells from pre-existing
vessels. New vessel formation is a key component of many
pathologic conditions, and occurs in the retina in response to
prolonged hypoxia, contributing to visual loss in retinopathy of
prematurity (ROP), age-related macular degeneration (AMD) and
diabetic retinopathy (DR). Together, these afflict people in all
stages of life from birth through late adulthood and account for
most instances of legal blindness.
ROP was reported at least 60 years ago in premature infants
[1,2] and there are 15,000 newborns in the United States that
are affected each year [3,4]. This represents the leading cause
of blindness in children. Despite new therapeutic approaches
that have improved the prognosis of newborns with ROP such
as pegaptanib (Macugen), bevacizumab (Avastin) and ranibizu-
mab (Lucentis), unmet need remains such as the need for
multiple injections and affordability [5,6]. The pathogenesis of
ROP, or oxygen-induced retinopathy (OIR) is organized in two
distinct phases. The first, ischemic phase, involves hyperoxia-
induced arrest in vascular development and vaso-obliteration.
The second, vaso-proliferative phase is thought to occur when
the avascular retina becomes ischemic and triggers the release of
pro-angiogenic factors [7]. This leads to aberrant retinal
neovascularization characterizing human ischemic retinopathies.
OIR is regulated by key factors such as vascular endothelial
growth factor (VEGF). Retinal neovascularization is suppressed by
agents that bind VEGF or block VEGF receptors [8]. A range of
other mediators have also been implicated in the pathogenesis of
ocular neovascular disease, including fibroblast growth factor-2
(FGF-2), matrix metalloproteinase-2 (MMP-2), MMP-9, insulin-
like growth factor (IGF)-1 and angiopoietin [9–12]. The 42 kDa
basic region leucine zipper transcription factor c-Jun regulates the
expression of VEGF and a range of pro-angiogenic genes and
controls cellular processes such as proliferation, transformation
and apoptosis [13].
‘‘10–23’’ DNAzymes such as Dz13 that targets c-Jun are single-
stranded synthetic all-DNA catalysts that comprise a cation-
dependent catalytic core of 15 deoxyribonucleotides [14–17].
These bind a complementary sequence through Watson-Crick
base pairing and cleave target mRNA via a de-esterification
reaction. DNAzymes are relatively small, inexpensive to synthesize
and resist nuclease degradation. Here for the first time we
explored the ability of Dz13 to reduce retinal microvascular
density in an OIR model in mice with pre-existing retinal
angiogenesis and compared Dz13 efficacy against that of VEGF-A
antibodies. We also interrogated the effect of the DNAzyme on
visual behavior and its impact on changes in gene expression in the
eye.
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Materials and Methods
Cell Culture
Human microvascular endothelial cells (HMEC) (American
Type Culture Collection, Manassas, VA) were maintained in
MCDB131 media (Gibco) supplemented with 10% fetal bovine
serum (FBS), hydrocortisone (500 mg/ml, Sigma), epidermal
growth factor (0.01 mg/ml, GIBCO), L-glutamine (2 mM) and
antibiotics [18]. The cells were seeded at 16105 cells/ml and sub-
cultured after detachment with 0.05% trypsin/5 mM EDTA.
Cell Transfection and Proliferation Assays
Typically, 3500 HMEC were seeded into 96-well plates. After
approximately 24 h with 70% confluence, MCDB 131 media with
10% FBS was replaced with serum free MCDB 131 media for
further 20 h for serum arrest. Cells were then transfected with
DOTAP/DOPE [19] with Dz13, 59-CGG GAG GAA GGC
TAG CTA CAA CGA GAG GCG TTG (39-39 T)-39 and
Dz13scr, 59-GCG ACG TGA GGC TAG CTA CAA CGA GTG
GAG GAG (39-39 T) -39 at a ratio of 3:1 (3 ml of 1 mg/ml
DOTAP/DOPE to 1 mg DNA) at concentration of 0.2–0.4 mM.
After 4 h of transfection, the media was replaced with 10% FBS
MCDB 131 for further 48 h. Media was removed and cells were
washed with PBS. Cells were trypsinized and the suspension per
well was quantified in an automated Coulter counter (Z series,
Coulter).
Lactate Dehydrogenase (LDH) Assay
LDH activity in the supernatants of transfected HMEC was
determined using the Cytotoxicity Detection Kit according to the
manufacturer’s instructions (Roche).
Endothelial Tubule Formation Assays
HMEC (30000 cells) were grown and transfected as described
above in 6-well plates. The cells were trypsinized and 3000 cells
seeded onto 100 ml Matrigel (BD Bioscience) in 96-well plates in
medium with or without 5% FBS. Photographs of the tubules were
taken at hourly intervals using a Nikon eclipse TE2000-S
fluorescence microscope. Tubules .3 mm in 96 well plates were
quantified in each of 4 random fields using NIH Image J software.
In vitro Wound Repair
HMEC were grown and transfected as described in 6-well plates
and serum free or 5% FBS conditioned MCDB 131 then placed
on the cells and the cells cultured until a monolayer of cells was
formed. The cells were injured by scraping with a sterile toothpick
and were left for 48 h. The denuded zone was standard in every
case and created in each well by the uniform linear stroke of a
sterile toothpick. Uniformity of width in the denuded zone
(300 mm) was confirmed under phase contrast microscopy
immediately after scraping injury. Calcein (500 mM) was incubat-
ed with the cells for 20 min prior to fluorescence microscopy.
Western Blotting
Protein concentrations in the extracts were determined using
the micro-BCA assay (Pierce, Rockford, IL). Equal amounts of
total protein were loaded onto 10–12% polyacrylamide gels.
Western blotting was performed essentially as described [20,21]
using commercial rabbit or goat antibodies (Santa Cruz Biotech-
nology, Abcam, R&D Systems): rabbit monoclonal c-Jun antibod-
ies were used at 1:500 dilution, rabbit polyclonal VEGF-A
antibodies were used at 1:500, rabbit polyclonal FGF-2 antibodies
were used at 1:1000, and rabbit polyclonal MMP-2 antibodies
were used at 1:500. Secondary polyclonal swine anti-rabbit
antibodies were obtained from Dako and used at 1:1000.
Unbiased loading was confirmed by probing for beta-actin
(Sigma).
Murine Model of Oxygen-induced Retinopathy
C57BL/6 mice and postnatal day 2 (P2) pups were purchased
from Australian Resources Centre (Perth). Postnatal P6.5–P7 mice
were exposed to hyperoxia (75% oxygen) for 4 d in Quantum-Air
Maxi-Sealed cages (Hereford, UK) [20]. Following this period of
hyperoxia, the mice were returned to normoxia for 5 d and
intravitreal injections were performed (I-0). This is approximately
a week after complete coverage of the retina by the superficial
plexus [22], and after the hyperoxia/normoxia cycle that increases
pathologic retinal angiogenesis and vascular density. Intravitreal
injections of 20 mg Dz13 or Dz13scr (in 1.68 ml H2O containing
0.2 ml of 1 mg/ml N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethy-
lammonium methyl-sulfate and 1,2-dioleoyl-sn-glycero-3-phos-
phoethanolamine, i.e., DOTAP and DOPE), its vehicle alone
(H2O, DOTAP/DOPE) or 10 mg/ml VEGF-A antibodies (Roche
CAS 216974-75-3) (in PBS, pH 7.4) [23] or its control (10 mg/ml
IgG in PBS, pH 7.4) were performed with 26-gauge beveled
needles attached to a micro-volume syringe (SGE Analytical
Science syringe Melbourne, Australia). The mice were left at room
oxygen for a further 10 d (I-10) and pup eyes were then enucleated
and fixed in 10% formalin in PBS for immunohistochemistry or
TRIzol (Invitrogen) for RNA extraction. Mice were deeply
anesthetized with ketamine and xylazine for all procedures.
Experiments were performed with and without operator blinding.
DNAzyme Localization Studies
Twenty mg of FITC-DNAzyme (TriLink BioTechnologies) was
injected intravitreally in anaesthetized pups in the OIR model as
described above. Eyes were removed from the pups 2 d after the
injections and were visualized under a fluorescence microscope
(Olympus DP70).
Histology and Immunohistochemical Analysis
Experimental and control mice were sacrificed at I-0 or I-10,
eyes enucleated, fixed in 10% formalin overnight, and embedded
in paraffin. Serial 5 mm cross sections of whole eyes were cut
sagitally, at a fixed distance from the optic nerve (0, 50, 100 mm),
and stained with H&E. Blood vessels from each group were
quantified under light microscopy (3 sections per eye) as
erythrocyte-filled vessels and vessels located on the vitreal side of
the inner limiting membrane [24] were taken into consideration.
With n= 6–8 eyes per group and 3 sections assessed per eye, each
group represents 18–24 separate measurements. Immunohisto-
chemical staining was performed on formalin-fixed paraffin-
embedded tissues with rabbit polyclonal anti-mouse c-Jun
antibodies at 1:200 dilution or rat polyclonal anti-mouse CD34
antibodies at 1:500 dilution (Santa Cruz and Abcam), and
biotinylated goat anti-rabbit or rabbit anti-rat secondary antibod-
ies at 1:200 (Dako). Each specimen was processed together with its
negative control that was IgG primary antibody (Santa Cruz).
Visual Placement Test
Mice had their whiskers trimmed to a length of 1 cm from the
skin at I-10 for the visual placement test. The animals were lifted
by the base of their tails to 30 cm above the cage, then lowered
vertically toward the cage top at a steady speed of 1 cm/s [25].
The ability of the mice to reach the cage top with their forepaws
was determined 5 times for each mouse. Data is expressed as the
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number of forepaw-reaching episodes that did, or did not involve
the whiskers touching the cage surface. Two independent visual
placement experiments were performed, one under blinded
conditions. There was no significant difference between these
experiments.
RNA Isolation
Eyes were enucleated and placed in TRIzol on dry ice
according to the manufacturer’s instructions (Purelink RNA
Minikit, Invitrogen).
Quantitative Real-Time PCR
qPCR was carried out using Rotor-Gene 3000 (Corbett Life
Science). The reaction was set in a final volume of 20 ml
containing 0.5 ml of cDNA, 10 ml of SYBR Green Master Mix
(Applied Biosystems), 0.6 ml of 10 mM of forward and reverse
primer (Sigma), and 8.9 ml of DNase-free water. Murine c-jun
primers were: forward, 59-ACT CCG AGC TGG CAT CCA-39,
reverse, 59- CCC ACT GTT AAC GTG GTT CAT G-39. PCR
conditions were: 95uC for 10 min followed by 35 cycles at 65uC
for 20 sec, 72uC for 20 sec. Murine MMP-2 primers were:
forward 59-GGG ACA AGA ACC AGA TCA CAT AC-39,
reverse, 59-CTT CTC AAA GTT GTA GGT GGT GG-39. PCR
conditions were: 95uC for 10 min followed by 28 cycles at 57uC
for 30 sec and 72uC for 40 sec. Murine MMP-9 primers were:
forward 59-CCA AGG GTA CAG CCT GTT CCT-39, reverse,
59-GCA CGC TGG AAT GA C TAA GC-39. PCR conditions
were 95uC for 10 min followed by 30 cycles at 52uC for 20 sec and
72uC for 20 sec. Murine MMP-12 primers were: forward 59–TTT
GAC CCA CTT CGG CC-39, reverse 59–GTG ACA CGA CGG
AAC AG-39. PCR conditions were 95uC for 10 min followed by
30 cycles at 59uC for 20 sec and 72uC for 20 sec. Murine MMP-
13 primers were: forward 59–GTA ATC GCA TTG TGA GAG
T-39, reverse 59–ATC AGG TGA TCC TTG GG-39. PCR
conditions were 95uC for 10 min followed by 30 cycles at 56uC for
20 sec and 72uC for 20 sec. Murine VEGF-A primers were:
forward 59–ATG AAC TTT TCT GCT GTC TTG GGT G-39,
reverse 59–TCA CCG CCT CGG CTT GTC ACA T-39. PCR
conditions were 95uC for 10 min followed by 30 cycles at 68.5uC
for 20 sec and 72uC for 20 sec. Murine VEGF-C primers were:
forward 59–AAC GTG TCC AAG AAA TCA GCC-39, reverse
59–AGT CCT CTC CCG CAG TAA TCC-39. PCR conditions
were 95uC for 10 min followed by 30 cycles at 65uC for 20 sec and
72uC for 20 sec. Murine FGF-2 primers were: forward 59–GTC
ACG GAA ATA CTC CAG TTG G-39, reverse 59–CCC GTT
TTG GAT CCG AGT T-39. PCR conditions were 95uC for
10 min followed by 30 cycles at 60uC for 20 sec and 72uC for
20 sec. Murine beta-actin primers were, forward, 59-AGC CAT
GTA CGT AGC CAT CC-39, and reverse, 59-CTC TCA GCT
GTG GTG GTG AA-39.
Microarray Analysis and GSEA
Total RNA (10 ml at 50 ng/ml concentration) from 8–10 pooled
whole eyes was used to prepare labeled probes for microarray
analysis with a one-cycle protocol (Affymetrix Gene 1.0 ST arrays,
University of New South Wales Ramaciotti Centre for Gene
Function Analysis, Australia). Two independent experiments were
performed, one under blinded conditions. Normalization and
probe set summarization was performed using the robust multi-
chip average [26] implemented in the Affy library [27] from R/
Bioconductor [28,29]. Control probe sets were removed leaving
28815 probe sets on the array. Differential gene expression was
assessed for each probe set using Limma [30]. Gene Set
Enrichment Analysis was run with the GenePattern tool GSEA
preranked using a ranked list of fold-changes derived from Limma
analysis. Of the 3272 gene sets in the curated gene set collection
786 gene sets were filtered out by the gene set size filter (min= 15,
max= 500) leaving 475 gene sets upregulated in Dz13 and 2011
downregulated in Dz13. All analyses were performed using Gene
Pattern software [31] and are available at http://pwbc.garvan.
unsw.edu.au/gp. Microarray data are accessible from GEO:
GSE37898.
Animal Ethics and Statistical Analysis
Animal experiments were approved by the Animal Care and
Ethics Committee, University of New South Wales. All values are
expressed as the mean6 s.e.m. The data was analysed by one-way
ANOVA followed by Bonferroni-Dunn post hoc analysis (Graph-
Pad Prism 5) and/or Student’s t-test comparing individual groups.
Results
Dz13 in DOTAP/DOPE Inhibits Retinal Microvascular
Density in a Modified OIR Model
We evaluated the therapeutic effect of Dz13 in mice with pre-
existing retinal angiogenesis. The OIR model has mainly been
used to evaluate the effect of candidate molecules to inhibit the
onset of retinal angiogenesis. Here we employed this system in a
therapeutic ‘‘curative’’ rather than preventative setting. Dz13
(20 mg in 1.68 ml H2O containing DOTAP/DOPE) was admin-
istered once, intravitreally to I-0 C57BL/6 mice. These mice had
previously been exposed to 75% oxygen for 4 d and returned to
room air to render the inner retina relatively hypoxic [24].
Alternatively the mice were injected with Dz13scr (20 mg) or the
vehicle alone. Ten days following DNAzyme administration, at I-
10, the mice were sacrificed, the eyes enucleated, cross-sectioned
and stained. Retinal microvascularity in H&E- (Fig. 1A) and
CD34- (Fig. 1B) stained sections from control mice increased
under these conditions at I-0, and levels remained elevated by I-
10. CD34 has previously been used to quantify retinal microvas-
cular density after OIR in C57BL/6J mice [32] and as an
endothelial marker in human choroidal neovascularization [33].
At I-10, Dz13 dramatically reduced the number of retinal blood
vessels (Figs. 1A & B). In contrast, the same load of its scrambled
arm counterpart, Dz13scr, did not affect retinal vascular density
compared with the vehicle group (Figs. 1A & B). Fluorescence
microscopy was performed to determine whether the DNAzyme
was absorbed into the subretinal space. FITC-Dz13 (20 mg) in
DOTAP/DOPE was injected intravitreally on I-0 and fluores-
Figure 1. Dz13 reduces pre-existing retinal microvascular density and penetrates the subretinal space. C57BL/6 mice were exposed to
75% oxygen for 4 d and returned to room air for 5 d. Dz13 or Dz13scr (20 mg in DOTAP/DOPE) was injected intravitreally (I-0). After 10 d (I-10), the
animals were sacrificed, the eyes enucleated, cross-sectioned and stained with H&E (A) or, alternatively, with antibodies to CD34 (B). Blood vessels on
the vitreal side of the inner limiting membrane were quantified by counting erythrocyte-filled vessels in H&E-stained sections or CD34-stained vessels
per section. ‘‘Blood vessel number’’ represents the mean number of blood vessels in 3 parallel cross-sections (5 mm each) per retina at 3 distances
from the optic nerve (0, 50, 100 mm). Blood vessels are denoted by arrows. n = 6–8 eyes per group. Data is representative of 2 or more experiments.
FITC-Dz13 (20 mg) in DOTAP/DOPE was injected intravitreally on I-0 and fluorescence intensity at I-2 was determined using NIH Image J software (C).
*denotes P,0.05 relative to vehicle or Dz13scr.
doi:10.1371/journal.pone.0039160.g001
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Figure 2. Dz13 inhibits c-Jun, FGF-2, VEGF-A, MMP-2 and MMP-9 expression in eyes of OIR mice. (A) Immunohistochemical analysis for
c-Jun immunoreactivity in the retina of I-10 mice treated on I-0 with Dz13, Dz13scr or vehicle. Where indicated, IgG was used as the primary antibody
as a negative control. Blood vessels are denoted by arrows. n = 6–8 eyes per group. (B) qPCR analysis on eyes of I-10 mice for c-jun, FGF-2, VEGF-A,
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cence intensity was evaluated in cross-sections of the retina at I-2.
FITC-Dz13 localized subretinally (Fig. 1C), whereas eyes injected
with Dz13 without the label or DOTAP/DOPE showed no
evidence of retinal fluorescence except for autofluorescence in the
retinal pigment epithelium, as previously observed [34] (Fig. 1C).
Dz13 Inhibits Expression of c-jun and c-Jun-dependent
Genes in Eyes of OIR Mice
Immunohistochemical staining revealed that c-Jun immunore-
activity in microvessels on the vitreal side of the inner limiting
membrane in OIR mice was inhibited by Dz13. c-Jun expression
at I-10 was observed in retinal microvessels in the Dz13scr and
vehicle groups, but was barely detectable in the Dz13 group
(Fig. 2A). Since c-Jun, as a transcription factor, controls the
expression of multiple other genes, we examined the effect of Dz13
on genes induced under conditions of OIR by comparative
microarray analysis. This approach was used to compare the
expression profile between Dz13, Dz13scr and vehicle (DOTAP/
DOPE)-treated eyes at I-10 (Fig. S1, right). When comparing the
Dz13 and Dz13scr groups we found 251 probe sets had a log2
fold-change .1.5 (Fig. S1, upper left). c-jun was one of the 187
probe sets downregulated by Dz13 whereas 64 probe sets were
upregulated. Among other genes induced by OIR that were
inhibited by Dz13 were a range of pro-angiogenic growth factors
and matrix-degrading enzymes (Fig. S1, right). Quantitative
real-time PCR (qPCR) analysis of eyes of I-10 mice revealed that
Dz13 inhibited the OIR-inducible expression of not only c-jun
mRNA relative to Dz13scr, but also that of FGF-2, VEGF-A,
VEGF-C, MMP-2, MMP-9, MMP-12 and MMP-13 (Fig. 2B).
Gene Set Enrichment Analysis of Eyes of OIR Mice
Treated with DNAzyme
In order to understand the genome-wide effect of Dz13 vs
Dz13scr the log2 fold-changes of all 28815 genes on the array were
inputed into gene set enrichment analysis (GSEA) [35] and
compared to the curated gene sets (c2all) from version 3 of the
Molecular Signatures Database (MSigDB) [35]. The curated gene
sets are sourced from pathway databases as well as results from
published microarray studies. Unlike individual gene analysis
GSEA shifts the emphasis from the role played by single genes to
groups of genes (gene sets). It also offers the advantage that no
thresholding of genes is performed and all genes on the array are
used. At an FDR ,25%, 765 gene sets were significantly
downregulated by Dz13 while only 3 gene sets were significantly
upregulated (Table S1). An overwhelming number of these
downregulated gene sets, including those containing MMP-12 and
MMP-13 (Fig. S1, lower left) are associated with cancer (Table
S2).
Dz13 Inhibits Endothelial Cell Proliferation, Migration and
Tubule Formation in vitro
Angiogenesis is a complex process involving endothelial cell
proliferation and migration. We next confirmed that Dz13 (in
DOTAP/DOPE) could inhibit these key cellular processes in
human microvascular endothelial cells (HMEC). Serum-inducible
HMEC proliferation after 2 d was inhibited by 0.4 mM of Dz13,
but not Dz13scr (Fig. 3A). The inhibitory effects of Dz13 on
endothelial cell proliferation were not due to toxicity. We
performed an assay for lactose dehydrogenase (LDH) over a
range of concentrations and quantified cell numbers after
trypsinization. Fig. 3B demonstrates that Dz13 inhibits endothe-
lial proliferation at 0.4 mM without toxicity. Dz13 (0.4 mM) also
blocked HMEC regrowth into the denuded zone 2 d following in
vitro scraping injury, whereas Dz13scr had no effect (Fig. 3C).
Angiogenesis involves the ordered assembly and alignment of
endothelial cells. In vitro, endothelial cells spontaneously align and
form a three-dimensional tubular capillary-like network within
hours of plating on Matrigel, a commercial basement membrane
matrix mixture. HMEC formed tubules within 4–6 h in this model
(Fig. 3D). Dz13 in DOTAP/DOPE completely blocked tubule
formation, whereas Dz13scr had no effect (Fig. 3D). Dz13
(0.4 mM) in DOTAP/DOPE inhibited the inducible c-Jun
expression in HMEC exposed to serum for 1 h (Fig. 3E). Dz13
in this formulation also inhibited the expression of VEGF-A, FGF-
2 and MMP-2 in these cells, whereas Dz13scr had no inhibitory
effect (Fig. 3E).
Comparison of Dz13 to VEGF-A Antibodies
We next compared the effect of Dz13 against a clinically-used
approach such as VEGF-A antibodies (akin to Lucentis) in this
model. I-0 mice were administered intravitreally with Dz13
(20 mg) in vehicle (H2O containing DOTAP/DOPE) or vehicle
alone, or VEGF-A antibodies [23] (10 mg/ml in PBS, pH 7.4) or
IgG in vehicle. Microvascular density at I-10 in all injected control
groups did not differ from that of uninjected I-0 eyes (Fig. 4A).
However, in eyes treated with Dz13 or VEGF-A antibodies, there
was virtually complete inhibition of retinal vascularity relative to
background (Fig. 4A). Importantly, Dz13 was as effective as
VEGF-A antibodies in the inhibition of retinal microvascular
density (Fig. 4A). This was further confirmed by immunohisto-
chemical analysis indicating reduced CD34+ blood vessels in Dz13
and VEGF-A antibody-treated eyes compared with vehicle and
IgG controls (Fig. 4B). Interestingly, although Dz13 reduced c-
Jun immunoreactivity in the retina, c-Jun expression was still
detected in VEGF-A antibody-treated eyes (Fig. 4C). This
suggests that, unlike Dz13, c-Jun may not be the primary means
by which VEGF-A targeting strategies effect inhibition of retinal
neovascularization in this model.
Effect of Dz13 Treatment in a Modified Forepaw Reach
Model
The preceding data provide a compelling anatomical demon-
stration of the capacity of Dz13 in DOTAP/DOPE to reduce pre-
existing microvascular networks in OIR. Lastly we determined
whether Dz13 could provide a behavioral advantage to mice using
a modified forepaw reach reflex model. This model has been used
by others to indicate the presence of sight and involves animals
being lowered from a fixed distance to the top of a cage [36] and
evaluating forepaw reach for the bars of the cage when brought
closer to the cage. Normal mice reached for the cage in almost
every instance, whereas mice subjected to OIR injected with
vehicle sensed the top of the cage poorly (Fig. 5). I-10 animals
treated with Dz13 (20 mg) sensed the top of the cage, whereas mice
injected with Dz13scr did not differ from the vehicle group
(Fig. 5). Our findings above show that retinal microvascular
density in the latter two groups was brought to background levels
in Dz13 mice (Figs. 1A & B, 4A). These findings thus
demonstrate that a once-only intravitreal administration of Dz13
VEGF-C, MMP-2, MMP-9, MMP-12 and MMP-13 mRNA. *denotes P,0.05 relative to vehicle and Dz13scr. Data is representative of 2 or more
experiments.
doi:10.1371/journal.pone.0039160.g002
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in DOTAP/DOPE to mice with pre-existing retinal microvascu-
larity provides measurable anatomic and behavioral benefit.
Discussion
Retinal neovascularization is hallmark in the pathogenesis of a
range of common ocular disorders. The objective of this study was
to determine the effect of Dz13 on pre-existing retinal micro-
vascularity, and compare it to a clinically-used approach. We also
aimed to demonstrate a behavioral consequence of Dz13
inhibition beyond retinal angiogenesis. In a modified OIR model,
Dz13, in a formulation containing DOTAP/DOPE caused a
marked reduction in retinal blood vessel density, whereas Dz13scr
had no effect. Dz13 inhibited the expression of c-Jun, and a range
of c-Jun dependent genes such as FGF-2, VEGF-A, MMP-2 and
MMP-9. This was supported by comparative microarray analysis
by GSEA, which shifts emphasis from individual genes to groups
of genes (gene sets). When comparing Dz13 to Dz13scr many
cancer gene sets were downregulated by Dz13. The DNAzyme
formulation also inhibited microvascular endothelial cell growth,
migration and tubule formation in vitro. Using a modified forepaw
reach model, mice treated with Dz13 sensed the top of the cage
unlike their vehicle or scrambled DNAzyme counterparts.
Dz13 was used in a clinically-relevant curative model in a
liposomal formulation. Analysis of cross-sections of Dz13-treated
retina by fluorescence microscopy revealed that the DNAzyme
localized subretinally. Local intravitreal delivery makes amenable
the use of a carrier with the DNAzyme. Interestingly, a carrier
does not appear to be essential in vivo. Oligonucleotides such as
DNAzymes have also been used in a range of animal models with
and without a transfection agent. Indeed, clinical trials of antisense
oligonucleotides have employed naked oligonucleotide with no
carrier. Physiologic delivery in vivo may be achieved through
endogenous mechanisms [37].
AMD and DR are leading causes of blindness in the Western
world. VEGF-A antibodies, delivered intravitreally, represent an
FDA-approved therapy in retinal diseases such as AMD and DR
[38,39] and include Lucentis (ranibizumab, Genentech) and
Avastin (bevacizumab, Genentech). A recent study from the
Comparison of AMD Treatments Trials (CATT) involving 1208
patients with neovascular age-related macular degeneration
demonstrated that Avastin and Lucentis are equally effective in
treating AMD, with mean change in visual acuity at 1 year the
primary outcome [40]. VEGF siRNA (bevasiranib, Opko
Health) used first in-class and delivered intravitreally, was found
to be safe and well-tolerated following repeated administration
until clinical trials were terminated in Phase III in 2009 due to the
trial being unlikely to meet its primary endpoint. It also appeared
that the siRNA approach did not inhibit through predicted
mechanisms [6,14,41]. In the present study, Dz13 reduced retinal
microvascular density as effectively as VEGF-A antibodies.
Interestingly, although Dz13 inhibited c-Jun, this was not observed
in the retina of mice treated with VEGF-A antibodies. This
suggests that antibody strategies targeting VEGF-A may reduce
retinal microvascular density by mechanisms independent of c-
Jun, even though VEGF-A stimulates and is itself induced by c-
Jun. Since it appears that mechanisms mediating the reduction in
blood vessel density by Dz13 and anti-VEGF-A antibodies are
likely to be different, future clinical strategies to reduce retinal
vascular density in ocular pathologies may benefit from the
combinatorial use of Dz13, VEGF-A antibodies and/or other
agents. We did not observe any evidence of toxicity as a
consequence of intravitreal Dz13 delivery or the OIR model.
Histological examination of retinas treated with Dz13 revealed no
discernable difference to Dz13scr- or vehicle-treated eyes, except
for reduced vascular density in the Dz13 group. There was no
evidence of retinal degeneration or retinal detachment. It is
difficult to determine with certainty whether Dz13 has inhibitory
effects on normal or pathologic vessels. It is nonetheless clear in
this model of pre-existing retinal vascularity that Dz13 reduces
vascular density stimulated by OIR to levels of the normal retina.
A recent article from our group demonstrates that the inhibitory
activity of Dz13 does not appear to involve CpG motifs and a Toll-
like receptor response [19].
Dz13 offers a number of advantages over VEGF-A antibodies.
DNAzymes being DNA are relatively small and inexpensive to
synthesize and resistant to nuclease degradation. The 39-39 linked
nucleotide modification to the DNAzyme prevents exonuclease
degradation, increasing stability [42]. Limitations that have been
reported in the use of VEGF-A antibodies include a lack of
neovascular membrane regression [43,44], besides the more
general requirement of multiple injections and potential risk of
complications from intraocular injections [45]. An emerging
approach is the VEGF Trap-Eye (Regeneron) which like
ranibizumab and bevacizumab, binds and neutralizes VEGF but
requires repeated administration [46]. c-Jun DNAzymes provide a
possible alternative to antibody-based therapy, especially if
combined with recently described ocular reservoir devices for
local drug delivery [47].
The pathogenic course in OIR progresses in a relatively
uniform pattern and is controlled by key regulatory mediators.
Dz13 suppressed the expression of VEGF-A, FGF-2, MMP-2 and
MMP-9. It also inhibited MMP-12 and MMP-13. Both these
proteinases play a crucial role in tumor angiogenesis and tissue
remodeling [48,49]. MMP-12 is involved in the breakdown of
extracellular matrix and tissue remodeling, while MMP-13 is
involved in the breakdown of extracellular matrix-collagen type II,
which is important in tumor invasion and metastasis. Targeting a
key transcription factor such as c-Jun over a single gene alone (e.g.,
VEGF-A) provides the additional advantage of suppressing the
expression of multiple effector genes, like those demonstrated here,
indirectly, through inhibition of an upstream transcriptional
regulator that is switched on in this pathology. The modified
Figure 3. Inhibition of endothelial cell proliferation, migration and tubule formation by Dz13 in vitro, and suppression of c-Jun and
c-Jun-dependent gene expression. (A) Effect of Dz13 (0.4 mM) on serum-inducible HMEC proliferation after 2 d. Endothelial cell proliferation was
quantified as the total number of cells per well (triplicate wells per group) in 96 well plates. (B) Toxicity and cell count in HMEC after 2 d. LDH activity
and cell counts were quantified in triplicate cells of a 96 well plate per group. The % Control (FBS) for the ‘‘1-LDH’’ plot was calculated by subtracting
LDH values (% LDH positive) in the Dz13-treated groups from 100% and expressing these as a percentage of LDH activity in the FBS control, and for
the proliferation plot, expressing cell numbers the Dz13-treated groups as a percentage of numbers in the FBS control. (C) Effect of Dz13 (0.4 mM) on
HMEC migration into the denuded zone (of 300 mm width) 2 d after in vitro scraping injury. Counts represent number of cells that have migrated into
the denuded zone in 3 random fields using NIH Image J software. Calcein was added for 20 min before quantification. (D) Effect of Dz13 (0.2 mM) on
tubule formation by HMEC on Matrigel. Tubules .3 mm in 96 well plates were quantified hourly in each of 4 random fields using NIH Image J
software. Representative images taken at the 6 h time point are shown in the figure. (E) Western blotting using extracts of growth-quiescent HMEC
exposed to 5% FBS for 1 h. SFM denotes serum-free medium. Blots were quantified by scanning densitometry. Data is representative of 2 or more
experiments. *denotes P,0.05 relative to control.
doi:10.1371/journal.pone.0039160.g003
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OIR model used in a curative setting here contrasts with Dz13’s
prevention of retinal angiogenesis [20]. The fact that GSEA
suggests that cancer-related gene sets are downregulated by Dz13
is consistent with Dz13 inhibition of endothelial cell proliferation
and migration, cellular processes that underpin retinal neovascu-
larization. This study also provides the first evidence that
intravitreal administration of a DNAzyme confers a behavioral
advantage to mice through forepaw extension. Such testing takes
Figure 4. Comparison of Dz13 with VEGF-A antibodies in the modified OIR model. (A) C57BL/6 mice (I-0) were injected with Dz13 (20 mg)
in DOTAP/DOPE or its vehicle control (H2O containing DOTAP/DOPE), VEGF-A antibodies (10 mg/ml) in PBS, pH 7.4 or IgG (10 mg/ml) in PBS, pH 7.4 and
eyes removed at I-10. VEGF-A antibody concentration was as per Ref [23]. Blood vessels on the vitreal side of the inner limiting membrane were
quantified by counting erythrocyte-filled vessels in H&E-stained sections (A), CD34-stained sections (B) or c-Jun-stained section (C). ‘‘Blood vessel
number’’ represents the mean number of blood vessels in 3 parallel cross-sections (5 mm each) per retina at 3 distances from the optic nerve (0, 50,
100 mm). n = 6–8 eyes per group. Blood vessels are denoted by arrows. *denotes P,0.05 relative to vehicle or IgG.
doi:10.1371/journal.pone.0039160.g004
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advantage of the forepaw extension reflex that occurs when a
suspended animal is faced with a surface [26,36] and provides a
simple surrogate measure of visual resolution. Dz13 treated mice
reached for the cage as well as normal mice, whereas the Dz13scr
mice only partially recognized the top of the cage. Our findings,
taken together, suggest that Dz13 may serve as a possible
therapeutic option in the management of retinal vascularization.
Supporting Information
Figure S1 Microarray analysis was performed compar-
ing the gene expression profile between Dz13, Dz13scr
and vehicle (DOTAP/DOPE) groups at I-10 among 28815
probe sets on the Affymetrix gene chip. Heat map color
blue represents low expression; red represents high expression.
Top left, The plot demonstrates fold-change for all probe sets on
the array. Fold-changes are ranked from the most upregulated (left
in red) to the most downregulated by Dz13 (right in blue). Most
genes fall within a log2 fold-change of,0.5 with the boxed regions
showing 251 probe sets with fold-changes .1.5. Lower left,
GSEA showing 2 enrichment plots of the Lee and Mueller gene
sets with a selection of genes downregulated by Dz13 within each
set listed, including MMP-12 and MMP-13 which are highlighted.
(TIFF)
Table S1 Curated gene sets with a Q-value (,0.05)
downregulated by Dz13. 230 gene sets had a Q-value less than
0.05.
(PDF)
Table S2 Summarized curated gene set terms with a Q-
value (,0.05) downregulated by Dz13. Since names given to
gene sets can be uninformative summarizing themes in collections
of gene sets can be difficult. Here we used unique words in the
names of each gene set and summarized the frequency of word
occurrence. A complete list of all curated downregulated gene sets
identified in GSEA is provided in Table S1.
(PDF)
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